Amphastar Pharmaceuticals (AMPH) Current Leases (2019 - 2026)

Amphastar Pharmaceuticals' Current Leases history runs 8 years deep, the most recent figure standing at $9.7 million for Q1 2026.

• On a quarterly basis, Current Leases rose 25.29% year-over-year to $9.7 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 25.29% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, up 16.52% from the prior year.
• Current Leases advanced to $9.7 million in Q1 2026 per AMPH's latest filing, from $7.9 million in the prior quarter.
• Across five years, Current Leases topped out at $9.7 million in Q1 2026 and bottomed at $3.0 million in Q1 2023.
• The 5-year median for Current Leases is $3.9 million (2024), against an average of $5.1 million.
• Across the five-year window, Current Leases decreased 11.43% in 2022 and soared 97.17% in 2025, its largest moves.
• Year by year, Current Leases stood at $3.0 million in 2022, then soared by 30.07% to $3.9 million in 2023, then surged by 74.19% to $6.8 million in 2024, then climbed by 16.52% to $7.9 million in 2025, then rose by 22.41% to $9.7 million in 2026.
• Per Business Quant, the three latest AMPH Current Leases figures stand at $9.7 million (Q1 2026), $7.9 million (Q4 2025), and $7.8 million (Q3 2025).